Compare The Vita Coco Company Inc (COCO) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
The Vita Coco Company Inc vs Novo Nordisk A/S — how do they compare? The Vita Coco Company Inc trades at $75 (market cap $4.23B), while Novo Nordisk A/S trades at $50.56 (market cap $214.94B). The key difference: Novo Nordisk A/S is far larger — about 50.8× The Vita Coco Company Inc's market cap, and Novo Nordisk A/S pays a 3.67% dividend while The Vita Coco Company Inc pays none. Which is the better fit depends on your goals.
| COCO | NVO | |
|---|---|---|
Market Cap | $4.23B | $214.94B |
Sector | Technology | Health |
52-Week High | $84.02 | $71.70 |
52-Week Low | $32.30 | $35.29 |
Enterprise Value | $4.04B | $233.91B |
Dividend Yield | — | 3.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
COCO trades at $74.635, up 4.53% today, with a bullish technical signal and strong earnings momentum after beating Q1 2026 EPS estimates. The company reported 37% YoY revenue growth in Q1 2026, with management raising full-year guidance. Analysts maintain a $78.00 consensus price target, with 60% recommending Buy. Key support lies at $72, with resistance at $76.
Outlook remains positive driven by international expansion and dominant market position, but elevated valuation multiples pose risks. Upside depends on sustained execution against raised guidance, while any earnings miss or margin pressure could trigger volatility. The stock offers growth exposure but requires monitoring of competitive and consumer spending trends.
Novo Nordisk (NVO) trades at $49.28, down 0.4% on the day, with strong technical momentum indicated by bullish moving averages and a neutral RSI near 63. The company demonstrates robust fundamentals with a P/E of 11.83, net income margin of 37.2%, and consistent earnings beats in recent quarters. Recent news highlights competitive strength in GLP-1 drugs, including Wegovy pill adoption outpacing Eli Lilly's offering.
Outlook remains positive given analyst consensus of 57.9% buy ratings and intrinsic value estimates near $90, though risks include prescription slowdown concerns and rising debt-to-asset ratios. The stock presents a growth opportunity in pharmaceuticals with manageable near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About The Vita Coco Company Inc
The Vita Coco Company is a leading functional beverage brand specializing in coconut water. Its portfolio includes its flagship Vita Coco brand, clean energy drinks, and sustainable enhanced water products.
Read more on COCO →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
